Vamikibart in Participants With Uveitic Macular Edema

See also
Status	Clinical Trial	Phase
Completed	`NCT04455399` - Time Efficiency Comparison of Two IntraVitreal Injection Techniques	N/A
Recruiting	`NCT05642312` - A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema	Phase 3
Withdrawn	`NCT00958906` - Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT04455399 - Time Efficiency Comparison of Two IntraVitreal Injection Techniques

N/A

Recruiting

NCT05642312 - A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

Phase 3

Withdrawn

NCT00958906 - Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05642325
Study type	Interventional
Source	Hoffmann-La Roche
Contact	Reference Study ID Number: GR44278 https://forpatients.roche.com
Phone	888-662-6728
Email	global-roche-genentech-trials@gene.com
Status	Recruiting
Phase	Phase 3
Start date	March 23, 2023
Completion date	June 30, 2025

Vamikibart in Participants With Uveitic Macular Edema — Sandcat

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms